BR112012017093A2 - compostos orgânicos para a regulação de canais de íons vetoriais - Google Patents

compostos orgânicos para a regulação de canais de íons vetoriais

Info

Publication number
BR112012017093A2
BR112012017093A2 BR112012017093A BR112012017093A BR112012017093A2 BR 112012017093 A2 BR112012017093 A2 BR 112012017093A2 BR 112012017093 A BR112012017093 A BR 112012017093A BR 112012017093 A BR112012017093 A BR 112012017093A BR 112012017093 A2 BR112012017093 A2 BR 112012017093A2
Authority
BR
Brazil
Prior art keywords
regulation
amino acid
ion channels
organic compounds
vector
Prior art date
Application number
BR112012017093A
Other languages
English (en)
Portuguese (pt)
Inventor
Bernhard Fischer
Rudolf Lucas
Susan Tzostzos
Original Assignee
Apeptico Forschung & Entwicklung Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apeptico Forschung & Entwicklung Gmbh filed Critical Apeptico Forschung & Entwicklung Gmbh
Publication of BR112012017093A2 publication Critical patent/BR112012017093A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112012017093A 2010-01-14 2011-01-12 compostos orgânicos para a regulação de canais de íons vetoriais BR112012017093A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0004110A AT509267A1 (de) 2010-01-14 2010-01-14 Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PCT/AT2011/000014 WO2011085423A1 (de) 2010-01-14 2011-01-12 Zyklische peptide zur regulierung von vektoriellen ionenkanälen

Publications (1)

Publication Number Publication Date
BR112012017093A2 true BR112012017093A2 (pt) 2016-11-29

Family

ID=43970939

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012017093A BR112012017093A2 (pt) 2010-01-14 2011-01-12 compostos orgânicos para a regulação de canais de íons vetoriais

Country Status (16)

Country Link
US (1) US8754049B2 (https=)
EP (1) EP2523968B1 (https=)
JP (1) JP5771220B2 (https=)
KR (1) KR101865420B1 (https=)
CN (1) CN102770442B (https=)
AT (1) AT509267A1 (https=)
AU (1) AU2011206907B2 (https=)
BR (1) BR112012017093A2 (https=)
CA (1) CA2785185C (https=)
DK (1) DK2523968T3 (https=)
ES (1) ES2525381T3 (https=)
IL (1) IL220924B (https=)
NZ (1) NZ600818A (https=)
PL (1) PL2523968T3 (https=)
RU (1) RU2538597C2 (https=)
WO (1) WO2011085423A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
KR102217476B1 (ko) * 2013-04-23 2021-02-19 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 식 x₁-gqretpegaeakpwy-x₂의 고리 펩티드를 함유하는 동결건조물
US20160143266A1 (en) * 2013-04-23 2016-05-26 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
CA2939635A1 (en) * 2014-03-04 2015-09-11 Apeptico Forschung Und Entwicklung Gmbh Attenuation of intrapulmonary inflammation
IL258067B (en) * 2015-09-14 2022-08-01 Apeptico Forschung & Entwicklung Gmbh Circular protein for the treatment of pha type 1b

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968753A (en) * 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema
FR2839514A1 (fr) * 2002-05-07 2003-11-14 Centre Nat Rech Scient Nouveaux peptides cycliques, leur utilisation comme agents anti-microbiens
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
CN101007791A (zh) * 2007-01-12 2007-08-01 东华大学 一种氨基酸联苯化合物
CN101003520A (zh) * 2007-01-12 2007-07-25 陈志龙 一种缬氨酸丁酰联苯化合物
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
CN101298432B (zh) * 2008-05-30 2010-12-22 广州市星业科技发展有限公司 L-吡咯烷酮羧酸钠的制备方法
EP2296685B1 (en) * 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy

Also Published As

Publication number Publication date
AT509267A1 (de) 2011-07-15
DK2523968T3 (da) 2014-11-03
RU2538597C2 (ru) 2015-01-10
KR20120134100A (ko) 2012-12-11
KR101865420B1 (ko) 2018-07-13
IL220924B (en) 2018-04-30
AU2011206907B2 (en) 2016-06-02
PL2523968T3 (pl) 2015-03-31
NZ600818A (en) 2014-02-28
ES2525381T3 (es) 2014-12-23
JP2013517224A (ja) 2013-05-16
JP5771220B2 (ja) 2015-08-26
AU2011206907A1 (en) 2012-06-21
HK1174341A1 (en) 2013-06-07
CA2785185C (en) 2019-02-19
EP2523968B1 (de) 2014-09-10
US8754049B2 (en) 2014-06-17
CA2785185A1 (en) 2011-07-21
CN102770442A (zh) 2012-11-07
WO2011085423A1 (de) 2011-07-21
RU2012134322A (ru) 2014-02-20
EP2523968A1 (de) 2012-11-21
US20130072444A1 (en) 2013-03-21
CN102770442B (zh) 2015-09-23

Similar Documents

Publication Publication Date Title
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
EA201591276A1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
BR112012017093A2 (pt) compostos orgânicos para a regulação de canais de íons vetoriais
CA2889275C (en) Novel method for treating cardiac infarction using hmgb1 fragment
BR112012007979A2 (pt) moduladores de gpr40 de pirrolidina
EA202090053A3 (ru) Способы и композиции для лечения неэффективного эритропоэза
EA201390820A1 (ru) Слитый белок против рака
AR088392A1 (es) Macrociclos peptidomimeticos
CR20160229A (es) Inhibidires de bromodominio
EA201691146A1 (ru) Иммуногенное соединение
EA201000327A1 (ru) Белок
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
EA201401211A1 (ru) Улучшенные варианты фермента химозина
EA201391097A1 (ru) СОЕДИНЕНИЯ ДЛЯ СНИЖЕНИЯ ВЫРАБОТКИ β-АМИЛОИДА
BR112015010779A2 (pt) moduladores de di-hidropirazol gpr40
BR112013032711A2 (pt) composições farmacêuticas compreendendo sulbactam e inibidor de beta-lactamase
EA201390704A1 (ru) Соединения, ингибирующие металлоферменты
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
EP4567043A3 (en) Compounds for inducing tissue regeneration and uses thereof
EA201591180A1 (ru) Составы ингибитора lfa-1
CY1125043T1 (el) Ενωση τριπεπτιδιο, μεθοδος παρασκευης αυτης, και εφαρμογη αυτης
MA32183B1 (fr) Pyrimidylcyclopentanes hydroxylés utilisés comme inhibiteurs de protéine kinase akt

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]